Drug Delivery Devices Market by Product (Nebulizer, Inhaler, Syringe, Transdermal Patch, Drop Bottle, Pen Injector, Implantable Device), Therapeutic Area (Diabetes, Infectious, Oncology, Respiratory, Cardiovascular, Autoimmune) – Global Forecast to 2030

The Drug Delivery Devices Market is projected to reach $24.65 billion by 2030, at a CAGR of 7.6% from 2024 to 2030. Drug delivery devices are storage systems or similar technologies that are used to administer drugs or medicines into the body of a patient through various routes in order to achieve a therapeutic effect.

The growth of the drug delivery devices market is driven by several factors, including the increasing prevalence of chronic diseases, the advancements in disease treatment approaches, growing R&D expenditure in pharmaceutical and biotechnology industries, and increasing demand for advanced drug delivery systems. Factors such as emerging economies and technological advancements in drug delivery systems are a few of the opportunities that would help grow the market in the future. Biocompatibility and acceptability could be considered a challenge for the drug delivery devices market. However, manufacturing defects and a lack of awareness and education about newer drug delivery systems restrain the growth of the market.

Increasing Prevalence of Chronic Diseases

Chronic diseases, also known as non-communicable diseases, are disorders or conditions that are generally not caused due to an infection but by unhealthy habits or behaviors and also result in long-term health issues that require a long course of treatment. Some of the diseases included in this category are cardiovascular diseases, diabetes, chronic lung ailments, or even cancers. According to the World Health Organization (WHO), chronic diseases have been responsible for almost 74% of deaths across the world, growing due to risk factors, including the use of tobacco, unhealthy diets, physical inactivity, and inconsistent alcohol consumption.

Drug delivery systems have been considered to improve the therapeutic efficacy of targeted drugs, and also reduce systemic adverse effects, helping patients suffering from chronic diseases. As compared to conventional drugs, drug delivery using specific devices or systems also improves stability and compatibility, improved permeability, and precise targeting. For example, in the case of diseases such as Chronic Obstructive Pulmonary Disease (COPD), targeted delivery of drugs is being considered using inhalers as a delivery route due to quick absorption of the drug and faster onset of action.

The use of such drug delivery systems and devices helps achieve maximum pharmacological effects along with minimum side effects. The number of materials being used to deliver drugs has been increasing significantly and has shown great potential to treat chronic diseases, hence driving the growth of the market.

Click here to: Get Free Sample Pages of this Report

Technological Advancements in Drug Delivery Devices

Drug delivery devices are technologies or systems that store drug molecules and accelerate the reach of the drugs to various parts of the body depending on the disease that is being treated. This maximizes the therapeutic efficacy of the drug and minimizes its off-target accumulation in the body. In recent times, there have been a lot of changes and developments in order to provide a convenient, controlled, and targeted delivery of drugs. Furthermore, these changes have led to high efficacy and minimal off-target accumulation of the drug, therefore leading to the launches and approvals of several innovative products. For instance, in December 2022, Biocorp, a subsidiary of Novo Nordisk A/S (Denmark), announced the receival of the FDA 510(k) clearance to market Biocorp’s smart insulin pen device that automatically collects and records key treatment information and transmits it to a digital application. This data includes selected insulin units, date, and the time of injection.

Advanced drug delivery systems allow the patient to receive a tailored or specific amount of dose required, rapid, efficient, and sustained drug delivery, and minimize side effects of drugs. Advanced drug delivery systems and devices have proved to be useful for drug administration and are being suggested to be used as a carrier for novel drugs and also personalized treatment of patients based on the intensity and type of diagnosis or condition.

Several companies are aiming to develop new drug delivery systems in order to introduce new modalities of drugs. For instance, in April 2021, Gerresheimer AG (Germany) collaborated with SensAIR (Sweden) to present an on-body drug delivery device to help patients self-administer medication in a familiar environment such as their homes. This device can be used for drugs that have different viscosities and different requirements. This means that the size of the needle used and variable cartridge sizes can be adjusted through the patient’s smartphone.

Such developments aid the increase in the use of these technologies and increased patient compliance, hence leading to the growth of the market.

Key Findings of the Drug Delivery Devices Market Study:

The Parenteral Drug Delivery Systems Segment is Expected to Account for the Largest Share of the Market in 2024

Among the products, in 2024, the parenteral drug delivery systems segment is expected to account for the largest share of the market. Parenteral drug delivery systems are an invasive type of route taken to administer drugs directly into the bloodstream without undergoing first-pass metabolism. This can be done through the subcutaneous route, intradermal route, intramuscular route, or intravenous route. Pen injectors, syringes, autoinjectors, wearable injectors, needle-free injectors, and transdermal patches are some of the devices that are used to administer drugs through this route. The large share of the market is driven by factors such as an effective route for delivering active pharmaceutical substances that may have less bioavailability, a narrow therapeutic index, and faster effectiveness to the required organ.

The Diabetes Segment is Expected to Account for the Largest Share of the Market in 2024

Among therapeutic areas, in 2024, the diabetes segment is expected to account for the largest share of the market. Diabetes is a non-communicable and chronic disease that occurs when the body is not able to produce sufficient insulin or cannot use the produced insulin to regulate the sugar a person consumes. Various drug delivery devices are used to regulate and track insulin levels in a patient. Some of these devices include insulin pumps, insulin pens, wearable glucose monitors, and autoinjectors, among others. These devices regulate and track insulin levels and are connected with an application whose access is with the healthcare provider and close family to monitor glucose levels and administer insulin whenever needed. This segment is driven by factors such as a large variety of available devices to manage insulin levels, improved patient drug compliance, and less risk of side effects due to uniform administration of drugs.

Key Players

The key players profiled in the drug delivery devices market report are Koninklijke Philips N.V. (Netherlands), OMRON Corporation (Japan), GMP Laboratories of America, Inc. (U.S.), Gemini Pharmaceuticals, Inc. (U.S.), Resyca GmbH (Netherlands), Novartis International AG (Switzerland), Becton, Dickinson, and Company (U.S.), Lifelong Meditech Private Limited (India), Bright Pharma Caps, Inc. (U.S.), Gerresheimer AG (Germany), West Pharmaceutical Services, Inc. (U.S.), Eclam Medical ACS Ltd. (Israel), SMC Ltd. (U.S.), Owen Mumford Limited (U.K.), Haselmeier GmbH (Germany), SHL Medical AG (Switzerland), Ypsomed Holding AG (Switzerland), AptarGroup, Inc. (U.S.), Kindeva Drug Delivery L.P. (U.S.), Nemera Group (France), and Recipharm AB (Sweden).

The report includes a competitive landscape based on an extensive assessment of the market based on the route of administration/formulation and therapeutic area. The report also provides insights into the presence of major market players and their key growth strategies in the last three to four years.

Summary Table:

Scope of the Report:

Drug Delivery Devices Market, by Product

• Nasal & Pulmonary Drug Delivery Systems
  • Nebulizers
    • Jet Nebulizers
    • Ultrasonic Nebulizers
    • Mesh Nebulizers
  • Empty Inhalers
    • Metered-Dose Inhalers
    • Soft Mist Inhalers
    • Dry Powder Inhalers
  • Steamers
  • Nasal Sprays
• Parenteral Drug Delivery Systems
  • Syringes
    • Conventional Syringes
    • Safety Syringes
    • Prefilled Syringes
  • Pen Injectors
  • Autoinjectors
  • Needle Free Injectors
  • Wearable Injectors/On-Body Drug Delivery System
• Topical & Transdermal Drug Delivery Systems
  • Transdermal Patches
  • Wearable Patches
• Drop Bottles Drug Delivery Systems
  • Nasal Drop Bottles
  • Ocular Drop Bottles
  • Cochlear Drop Bottles
• Implantable Drug Delivery Devices
  • Inserts
  • Pumps
  • Drug Eluting Stents
• Insulin Pumps
• Intrauterine Devices
• Infusion Pumps

Drug Delivery Devices Market, by Therapeutic Area

• Diabetes
• Infectious Diseases
• Oncology
• Cardiovascular Diseases
• Respiratory Diseases
• Neurological Diseases
• Autoimmune Diseases

Key questions answered in the report: